2/6/2012 2:12 AM ET
(RTTNews) - Venus Remedies Ltd. has achieved another landmark by fetching its first patent grant from Japan patent office or JPO for its novel research product 'Vancoplus', which has been designed to curb the growing bacterial resistance specially caused by the notorious Methicillin-Resistant Staphylococcus or MRSA strain which is usually termed as one of the Superbugs.
The company intends to launch this research product in early 2015. Currently, Vancoplus is available in emerging markets and is under registration in many countries. Venus intends to our-license Vancoplus across patent protected regions to major pharmaceutical players.
The drug restricts the expression of efflux pump and down regulates the mec A gene and PVL expression by MRSA pathogens. This enables the drug to act against resistant strains and prevent development of resistance which drastically reduces the treatment time.
During the past four decades, MRSA has evolved from a controllable nuisance into a serious public health concern. Vancoplus is the only known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus Aureus) and multi-drug resistant bacteria, which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditis.
The market size of MRSA in the world accounts for $900 million. At present, it is growing with CAGR of 4.8 percent, which is estimated to reach to $1.2 billion by 2017. Studies indicate that the incidence of MRSA in the past few years has extensively increased worldwide, with the prevalence of MRSA in Japan, US and southern European countries ranging from 20 percent and 60 percent.
Having launched in the various emerging markets across the globe, Vancoplus has undergone various pre-clinical studies as per OECD guidelines, multi-centric Phase III and Phase IV clinical trials and efficacy is also established through a series of microbiological studies carried out as per CLSI guidelines.
The company has also received patent for Vancoplus from the US, South Africa, New Zealand and Ukraine. Vancoplus is a boon for the medical field as it it not only cost effective but also reduces treatment time. This patent grant for Vancoplus is valid up to February 2026.
Japan has a growing elderly population and high health expenditure with second largest per capital spending in the Asia Pacific region. The company is hopeful of gaining a fair share of the MRSA market. Methicillin-Resistant Staphylococcus Aureus is exceptionally critical to infection treatment and control in the health-care setting. MRSA has been detected at high levels in Japan.
1
2
Next Page